Trial Profile
A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab (Mabthéra® ) after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Chlorambucil; Cyclophosphamide; Doxorubicin; Fludarabine; Mitoxantrone; Prednisolone; Vincristine
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PRIMA
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 24 Jul 2019 Results assessing PFS and overall survival after 9 years of follow-up (n=1018) published in the Journal of Clinical Oncology
- 20 Feb 2018 Results of gene-expression profiling score for prediction of outcome in patients with follicular lymphoma, published in the Lancet Oncology